New cancer drug RP3 shows promise in early trial
NCT ID NCT04735978
First seen Sep 30, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-stage study tests a new drug called RP3, alone or with an immunotherapy, in 123 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the best dose. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Churchill Hospital
Oxford, OX3 9DU, United Kingdom
-
Hospital Clinic Barcelona
Barcelona, 08036, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy
Villejuif, 94805, France
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3
Madrid, 28050, Spain
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Merseyside, CH63 4JY, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University General Hospital Attikon
Athens, 12462, Greece
-
University of Athens
Athens, 11527, Greece
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital)
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.